The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.
about
Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosisIncreased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcomeCurrent concepts in the diagnosis and classification of renal dysfunction in cirrhosis.Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study.Diabetes and alpha lipoic Acid.Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis.Preoperative fasting: an outdated concept?ADMA metabolism and clearance.Arginine de novo and nitric oxide production in disease states.The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.Cellular ADMA: regulation and action.Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patientsIncreased circulatory asymmetric dimethylarginine and multiple organ failure: bile duct ligation in rat as a model.Arginine and citrulline and the immune response in sepsis.Asymmetric dimethylarginine in the assessment of febrile neutropenia in hematological patients.Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis.Live and let die: asymmetric dimethylarginine and septic shock.Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine.Liver plays a central role in asymmetric dimethylarginine-mediated organ injury.Gut and liver handling of asymmetric and symmetric dimethylarginine in the rat under basal conditions and during endotoxemia.Asymmetric dimethylarginine in hematological malignancies: a preliminary study.Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C.Accumulation of symmetric dimethylarginine in hepatorenal syndrome.Assessment of asymmetrical dimethylarginine metabolism in patients with critical illness.New Developments in Hepatorenal Syndrome.Plasma dimethylarginines during the acute inflammatory response.Imbalance of arginine and asymmetric dimethylarginine is associated with markers of circulatory failure, organ failure and mortality in shock patients.Insulin, glucose control and multiple organ dysfunction syndrome
P2860
Q26795604-00E0F9FF-F963-4080-BBB8-99C17C260986Q33565412-A1E1AFBB-AFBB-434A-B879-2F7C0C7AB77AQ33811643-9F91EF0B-2B08-4315-A76C-2C04921060ADQ35544768-4B895914-A04D-46CF-A7B4-570EA7FFB430Q35564911-30A1AB7E-D9DD-4625-B854-75942A3993B6Q36083890-CBEDC442-546E-4C06-925E-47A175299D5BQ36165739-A41E1785-BE42-4CBC-82A8-5A640FB7890CQ36381017-FCA88B08-4F33-4C74-8EFC-16E63C7983D4Q36454194-E9261D98-D4CF-45D1-9482-7F09244F688FQ37313734-177AC5A6-F370-4F8B-9457-778A4DE36E83Q37399711-CA005648-B218-4D08-94B8-26BD09640555Q37420073-CE968E72-524F-4EAF-AA26-ADA0B78A625AQ38194032-59E5FBF3-7110-4CEF-9B43-283933B41773Q38362838-F39A44BA-8607-4E73-A023-EE6C6A6ADDDAQ38952110-D1EA61A1-7A0A-49BE-A88B-52A6AE0B54B7Q40038186-A69FC6E9-4B16-4E4C-8FE7-0959E89B1920Q40271492-ED8448FD-3E2B-4764-92C9-61FA1F424435Q42502690-9BFB13F7-CCF3-4180-A136-FE104EE7E963Q42575439-4192A6F6-AB2A-43EE-9766-CD088296CE97Q43905884-E40B051C-C7E1-43EB-A69F-9D20B8D0F6F4Q46216898-ED4788EB-CF8C-4521-BA83-8CA35CCBEE5EQ46296923-3A0127A7-99E8-442D-931C-0612F68027E1Q46870364-BB417537-CF62-489F-893B-67D3AE6787BCQ47356075-9A208B34-DACC-4492-9164-F98ECAEAB91EQ47807120-72C20BF2-8C73-4B87-A24B-D19068AC4D7FQ51383978-0E5DA5BB-4DCA-4AB8-8FF5-8F50B3C18417Q54546383-36111BFE-7A60-4441-80E9-F506924BE3FFQ57245133-4EC3E58E-B42C-456C-B456-B0C716DF6DAB
P2860
The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.
@en
The asymmetrical dimethylarginine
@nl
type
label
The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.
@en
The asymmetrical dimethylarginine
@nl
prefLabel
The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.
@en
The asymmetrical dimethylarginine
@nl
P2093
P356
P1433
P1476
The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis.
@en
P2093
P A M van Leeuwen
R J Nijveldt
T Teerlink
P304
P356
10.1054/CLNU.2002.0614
P577
2003-02-01T00:00:00Z